Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK

Rory J. McCrimmon, Edel Falla, Jo Zhou Sha, Abdul Jabbar Omar Alsaleh, Elisheva Lew (Lead / Corresponding author), Richard Hudson, Mike Baxter, Karen Palmer

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)
20 Downloads (Pure)

Abstract

Introduction: A cost-effectiveness analysis was conducted comparing a fixed-ratio combination (FRC) of insulin glargine 100 units/mL plus lixisenatide (iGlarLixi) versus the FRC of insulin degludec plus liraglutide (iDegLira) and the free-combination comparators insulin glargine plus dulaglutide (iGlar plus Dula) and basal insulin plus liraglutide (BI plus Lira).

Methods: The IQVIA Core Diabetes Model was used to estimate lifetime costs and outcomes for a cohort of patients with type 2 diabetes mellitus (T2DM) from the UK healthcare perspective. Initial clinical data for iGlarLixi were based on the randomized, controlled LixiLan-L trial and the relative treatment effects for comparators were based on an indirect treatment comparison using data from the AWARD-9 (iGlar plus Dula), LIRA ADD2 BASAL (BI plus Lira), and DUAL V (iDegLira) trials. Costs were derived from publicly available sources. Lifetime costs (in British Pound Sterling [£]) and quality-adjusted life-years (QALYs) were predicted; net monetary benefit (NMB) for iGlarLixi versus comparators was derived using a willingness-to-pay threshold of £20,000. Extensive scenario and sensitivity analyses were conducted.

Results: Estimated costs were lowest with iGlarLixi (£31,295) compared with iGlar plus Dula (£38,790), iDegLira (£40,179), and BI plus Lira (£42,467). Total QALYs gained were identical with iGlarLixi and iDegLira (8.438), and comparable with iGlar plus Dula (8.439) and BI plus Lira (8.466). NMB for iGlarLixi was positive versus all comparators (£10,603.86 vs. BI plus Lira; £7,466.24 vs. iGlar plus Dula; £8.874.11 vs. iDegLira).

Conclusion: In patients with T2DM with suboptimal glycemic control on basal insulin, iGlarLixi provides very similar outcomes and substantial cost savings, compared with other fixed and free combinations of insulins plus glucagon-like peptide-1 receptor agonists.

Original languageEnglish
Pages (from-to)3217-3230
Number of pages14
JournalDiabetes Therapy
Volume12
Issue number12
Early online date29 Oct 2021
DOIs
Publication statusPublished - Dec 2021

Keywords

  • Cost-effectiveness
  • Cost-utility
  • Dulaglutide
  • GLP-1 receptor agonist
  • iDegLira
  • iGlarLixi
  • Liraglutide
  • Type 2 diabetes mellitus
  • United Kingdom

Fingerprint

Dive into the research topics of 'Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK'. Together they form a unique fingerprint.

Cite this